AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37147725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adherence monitoring and support components
Number of subjects: 512
Study 37147725 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 512
Study 37147739 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation (tDCS) administered by caregivers under remote supervision.
Number of subjects: 40
Study 37147739 — intervention group
Group type: COMPARATOR
Intervention: Sham control (placebo) group receiving a non-active intervention.
Number of subjects: 40
Study 37147857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda
Number of subjects: 0
Study 37147857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37147864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based telerehabilitation (Pilates-TR)
Number of subjects: 30
Study 37147930 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring (HTM) plus urinary peptidomic profiling (UPP)
Number of subjects: 144
Study 37147930 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure telemonitoring (HTM) alone
Number of subjects: 144
Study 37148183 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy (PAP)
Number of subjects: 45
Study 37148183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 45
Study 37148183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia plus positive airway pressure (CBT-I+PAP)
Number of subjects: 45
Study 37148240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 59
Study 37148240 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 59
Study 37148249 — intervention group
Group type: EXPERIMENTAL
Intervention: Litifilimab (monoclonal antibody against BDCA2)
Number of subjects: 0
Study 37148249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37148266 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo
Number of subjects: 114
Study 37148266 — intervention group
Group type: COMPARATOR
Intervention: SRP + oral hygiene instructions (Control)
Number of subjects: 114
Study 37148266 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 0.12% chlorhexidine gluconate mouthrinse twice a day for 3 mo + rubber interproximal bristle cleaners twice a day for 6 mo (in subjects with diabetes)
Number of subjects: 114
Study 37148373 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring application for 8 weeks
Number of subjects: 222
Study 37148373 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 222
Study 37148375 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway ultrasound (US)
Number of subjects: 50
Study 37148395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 48
Study 37148395 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Quitting
Number of subjects: 48
Study 37148395 — intervention group
Group type: EXPERIMENTAL
Intervention: Countering Emotional Behaviors
Number of subjects: 48
Study 37148395 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (Study 2)
Number of subjects: 48
Study 37148474 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 84
Study 37148474 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Number of subjects: 84
Study 37148474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 37148474 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg or 150 mg
Number of subjects: 84
Study 37148485 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (Evrysdi)
Number of subjects: 525
Study 37148485 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical dual CYP3A-FMO3 substrates
Number of subjects: 525
Study 37148485 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinement of FMO3 ontogeny in the risdiplam model
Number of subjects: 525
Study 37148497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 396
Study 37148497 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinic agents
Number of subjects: 396
Study 37148580 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 70 years
Number of subjects: 3686
Study 37148580 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 70 years
Number of subjects: 3686
Study 37148652 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia (BATA)
Number of subjects: 73
Study 37148652 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 73
Study 37148652 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-reported homework completion (within BATA)
Number of subjects: 73
Study 37148652 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-reported homework completion (within BATA)
Number of subjects: 73
Study 37148652 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homework completion (between-person effect)
Number of subjects: 73
Study 37148831 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated high-flow nasal cannula (HFNC) therapy
Number of subjects: 18
Study 37148831 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 18
Study 37148899 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 526
Study 37148899 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 526
Study 37149000 — intervention group
Group type: EXPERIMENTAL
Intervention: IN-PEACE care coordination intervention (n=99)
Number of subjects: 201
Study 37149000 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=102)
Number of subjects: 201
Study 37148999 — intervention group
Group type: EXPERIMENTAL
Intervention: SafERteens BI + Text Messaging (TM)
Number of subjects: 400
Study 37148999 — intervention group
Group type: EXPERIMENTAL
Intervention: SafERteens BI + remote Health Coach (HC)
Number of subjects: 400
Study 37148999 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued intervention condition (maintenance)
Number of subjects: 400
Study 37148999 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized condition (stepped down)
Number of subjects: 400
Study 37148999 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued condition (maintenance)
Number of subjects: 400
Study 37148999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified condition (stepped up)
Number of subjects: 400
Study 37149056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus olanzapine
Number of subjects: 80
Study 37149056 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 80
Study 37149149 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine
Number of subjects: 15
Study 37149257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (exercise-based rehabilitation program consisting of two weekly sessions of physical exercise for 8 weeks and one educational session)
Number of subjects: 211
Study 37149257 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 211
Study 37149257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Number of subjects: 211
Study 37149443 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19) vaccination
Number of subjects: 0
Study 37149443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37149458 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab maintenance therapy
Number of subjects: 0
Study 37149595 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable accelerometers for measuring and monitoring motor behaviour during CareToy-Revised training
Number of subjects: 0
Study 37149647 — intervention group
Group type: EXPERIMENTAL
Intervention: Left portal vein shunt with 8-mm Viatorr stent
Number of subjects: 130
Study 37149647 — intervention group
Group type: COMPARATOR
Intervention: Right portal vein shunt with 8-mm Viatorr stent
Number of subjects: 130
Study 37149670 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevance Factor Variational Autoencoder (RF-VAE)
Number of subjects: 0
Study 37149701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen (2.5, 5 mg)
Number of subjects: 1440
Study 37149701 — intervention group
Group type: COMPARATOR
Intervention: High-dose tamoxifen (10, 20 mg)
Number of subjects: 1440
Study 37149701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (any dose)
Number of subjects: 1440
Study 37149709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, individualized lifestyle intervention
Number of subjects: 98
Study 37149709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 37149818 — intervention group
Group type: EXPERIMENTAL
Intervention: pIPOM
Number of subjects: 187
Study 37149818 — intervention group
Group type: COMPARATOR
Intervention: sIPOM
Number of subjects: 187
Study 37149821 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10131
Study 37149821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10131
Study 37149930 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC treatment
Number of subjects: 100
Study 37149930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37150129 — intervention group
Group type: EXPERIMENTAL
Intervention: IPRGC lenses (spectacles blocking light wavelengths that stimulate IPRGCs)
Number of subjects: 78
Study 37150129 — intervention group
Group type: COMPARATOR
Intervention: Control lenses (standard lenses)
Number of subjects: 78
Study 37150129 — intervention group
Group type: EXPERIMENTAL
Intervention: IPRGC lenses
Number of subjects: 78
Study 37150144 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment
Number of subjects: 501
Study 37150147 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to gliadin (AGA IgG)
Number of subjects: 0
Study 37150258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated brain radiation therapy (RT)
Number of subjects: 44
Study 37150411 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG
Number of subjects: 141
Study 37150411 — intervention group
Group type: COMPARATOR
Intervention: Oral intake
Number of subjects: 141
Study 37150411 — intervention group
Group type: COMPARATOR
Intervention: NGT
Number of subjects: 141
Study 37150797 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric method using index finger length to measure OVD (Sn-Me)
Number of subjects: 80
Study 37150797 — intervention group
Group type: COMPARATOR
Intervention: Standard method for measuring OVD
Number of subjects: 80
Study 37150895 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release melatonin (4 mg)
Number of subjects: 18
Study 37150895 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release melatonin (4 mg)
Number of subjects: 18
Study 37150952 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib (once-daily oral pill)
Number of subjects: 0
Study 37150952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive pill)
Number of subjects: 0
Study 37150952 — intervention group
Group type: COMPARATOR
Intervention: Apremilast (twice-daily oral pill)
Number of subjects: 0
Study 37150956 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 0
Study 37150956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37150956 — intervention group
Group type: COMPARATOR
Intervention: Apremilast
Number of subjects: 0
Study 37151084 — intervention group
Group type: EXPERIMENTAL
Intervention: Free dermal fat graft (FDFG)
Number of subjects: 78
Study 37151084 — intervention group
Group type: COMPARATOR
Intervention: Superficial musculoaponeurotic system (SMAS) flap
Number of subjects: 78
Study 37151105 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month testosterone replacement therapy (TRT)
Number of subjects: 69
Study 37151105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 37151329 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support services
Number of subjects: 0
Study 37151329 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV) and validated questionnaires
Number of subjects: 0
Study 37151571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation and auricular acupuncture (CIH therapies)
Number of subjects: 149
Study 37151571 — intervention group
Group type: COMPARATOR
Intervention: GW Health Education (GWHE) program
Number of subjects: 149
Study 37151894 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine cystatin C (uCysC)
Number of subjects: 40
Study 37151894 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine neutrophil gelatinase-associated lipocalin (uNGAL)
Number of subjects: 40
Study 37151894 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine kidney injury molecule 1 (uKIM-1)
Number of subjects: 40
Study 37151894 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-AKI+/FO+ infants
Number of subjects: 40
Study 37152307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dance and yoga intervention (8 months duration)
Number of subjects: 0
Study 37152307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37152360 — intervention group
Group type: EXPERIMENTAL
Intervention: vixotrigine 200 mg BID
Number of subjects: 265
Study 37152360 — intervention group
Group type: EXPERIMENTAL
Intervention: vixotrigine 350 mg BID
Number of subjects: 265
Study 37152360 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 265
Study 37152361 — intervention group
Group type: EXPERIMENTAL
Intervention: INTEP-AR model (large Infarct, NIHSS score, Thrombolysis, Endovascular treatment, Pneumonia, brain Atrophy, and Recanalisation)
Number of subjects: 2183
Study 37152361 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on the INTEP-AR model
Number of subjects: 2183
Study 37152362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MDA of ivermectin, albendazole, and azithromycin
Number of subjects: 7292
Study 37152362 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin and albendazole MDA followed by azithromycin MDA
Number of subjects: 7292
Study 37152362 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin MDA (stand-alone)
Number of subjects: 7292
Study 37152367 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline irrigation (100 ml saline pulse irrigation after cholangiography)
Number of subjects: 180
Study 37152367 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 180
Study 37152367 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Number of subjects: 180
Study 37152546 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision ACL autograft reconstruction
Number of subjects: 184
Study 37152546 — intervention group
Group type: COMPARATOR
Intervention: Primary ACL autograft reconstruction
Number of subjects: 184
Study 37152602 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-VET (20 sessions using a head-mounted display)
Number of subjects: 11
Study 37152602 — intervention group
Group type: COMPARATOR
Intervention: Waiting without VR-VET (4 weeks)
Number of subjects: 11
Study 37152926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (50 mmol/d sodium)
Number of subjects: 50
Study 37152926 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium diet (100 mmol/d sodium)
Number of subjects: 50
Study 37153086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus treatment for 6 months
Number of subjects: 50
Study 37153087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom (BV) phonophoresis with conservative treatment of medical ulcer care
Number of subjects: 100
Study 37153087 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment of medical ulcer care with ultrasound sessions only (control)
Number of subjects: 100
Study 37153087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom (BV) phonophoresis
Number of subjects: 100
Study 37153102 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional group intervention including Memory Compensatory Strategies, Problem-Solving, Emotion Regulation, Mindfulness, and Locus of Control.
Number of subjects: 30
Study 37153102 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional group intervention.
Number of subjects: 30
Study 37153118 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day initiation of HIV treatment
Number of subjects: 0
Study 37153118 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation of HIV treatment
Number of subjects: 0
Study 37153145 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF (20mg)/EVG (16mg) vaginal insert
Number of subjects: 16
Study 37153587 — intervention group
Group type: EXPERIMENTAL
Intervention: serplulimab 4.5 mg/kg plus nab-paclitaxel 260 mg/m² for up to 2 years (35 dosing cycles)
Number of subjects: 21
Study 37153702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray, 16 to 24 IU 3 times daily at mealtimes)
Number of subjects: 13
Study 37153702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (excipient-matched)
Number of subjects: 13
Study 37153702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal OXT
Number of subjects: 13
Study 37153702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 37153751 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 0
Study 37153751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37153770 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined olanzapine and sertraline
Number of subjects: 0
Study 37153770 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37153876 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy
Number of subjects: 0
Study 37154020 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban daily for 35 days
Number of subjects: 1284
Study 37154020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1284
Study 37154412 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR + ALLR
Number of subjects: 80
Study 37154412 — intervention group
Group type: COMPARATOR
Intervention: Isolated ACLR
Number of subjects: 80
Study 37154471 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 0
Study 37154471 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 0
Study 37154471 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 37154608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal Cells, details on dosage and duration not available
Number of subjects: 0
Study 37154608 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 37154609 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor
Number of subjects: 0
Study 37154888 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Survival Skills (DSS) intervention (6-week, 1-h per week)
Number of subjects: 92
Study 37154888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 37154986 — intervention group
Group type: EXPERIMENTAL
Intervention: Visensia Safety Index (VSI)
Number of subjects: 1529
Study 37154986 — intervention group
Group type: COMPARATOR
Intervention: Periodic Early Warning Score (EWS)
Number of subjects: 1529
Study 37154986 — intervention group
Group type: COMPARATOR
Intervention: Stable patients
Number of subjects: 1529
Study 37155004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone for 3 months after radiofrequency ablation
Number of subjects: 0
Study 37155004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37155004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study 37155132 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel Fumarate (DRF)
Number of subjects: 2190
Study 37155164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-informed treatment (PIT) with TCAs (nortriptyline, clomipramine, or imipramine) based on CYP2D6 and CYP2C19 genotypes.
Number of subjects: 111
Study 37155164 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment with standard initial TCA dosage.
Number of subjects: 111
Study 37155164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-informed treatment (PIT)
Number of subjects: 111
Study 37155171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine plus Digital Training
Number of subjects: 0
Study 37155171 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 37155168 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (reduction of rectal temperatures to between 33.0 °C and 34.0 °C for 72 hours)
Number of subjects: 408
Study 37155168 — intervention group
Group type: COMPARATOR
Intervention: Control (rectal temperatures maintained between 36.0 °C and 37.0 °C)
Number of subjects: 408
Study 37155168 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 408
Study 37155168 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 408
Study 37155223 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV e-report
Number of subjects: 357
Study 37155240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 2408
Study 37155240 — intervention group
Group type: COMPARATOR
Intervention: Web-based notification platform
Number of subjects: 2408
Study 37155264 — intervention group
Group type: EXPERIMENTAL
Intervention: BWL + BIAS
Number of subjects: 0
Study 37155264 — intervention group
Group type: COMPARATOR
Intervention: BWL
Number of subjects: 0